Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Laurus LabsBOM:540222 -0.32%66 Days Payable is 163.20 as of Mar. 2026, which is 22% above its 10-year median of 134.09. GuruFocus rates BOM:540222 with a GF Score™ of 66/100 and a GF Value™ of ₹704.96 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 927 Drug Manufacturers companies, Laurus Labs ranks better than 73.35% on this metric.
Laurus Labs's average Accounts Payable for the
three
months ended in Mar. 2026 was ₹12,521 Mil. Laurus Labs's Cost of Goods Sold for the
three
months ended in Mar. 2026 was ₹7,001 Mil.
Hence, Laurus Labs's Days Payable for the
three
months ended in Mar. 2026 was 163.20.
The historical rank and industry rank for Laurus Labs's Days Payable or its related term are showing as below:
BOM:540222'
s Days Payable Range Over the Past 10 Years
Min: 91.26 Med: 134.09 Max: 166.81
Current: 145.57
During the past 13 years, Laurus Labs's highest Days Payable was 166.81. The lowest was 91.26. And the median was 134.09.
BOM:540222's Days Payable is ranked better than 73.35% of 927
companies
in the Drug Manufacturers industry
Industry Median: 90.38
vs BOM:540222: 145.57
Laurus Labs's Days Payable
increased
from Mar. 2025 (111.75) to Mar. 2026 (163.20).
It may suggest that Laurus Labsdelayed paying its suppliers.
Laurus Labs Days Payable Related Terms
Laurus Labs Days Payable Historical Data
* Premium members only.
The historical data trend for Laurus Labs's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Laurus Labs's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Laurus Labs Days Payable vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Laurus Labs's Days Payable distribution charts can be found below:
* The bar in red indicates where Laurus Labs's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Laurus Labs's Days Payable for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Laurus Labs (BOM:540222) has a Days Payable of 163.20 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Laurus Labs and its competitors. This is 22% above median its historical median of 134.09. Over the past decade, Laurus Labs' Days Payable has ranged from 91.26 to 166.81. According to the industry distribution chart, Laurus Labs ranks #247 out of 927 companies in the Drug Manufacturers industry, placing it in the top 26.6%.
Is Laurus Labs' Days Payable too high?
Laurus Labs' current Days Payable of 163.20 is 22% above median its 10-year median of 134.09. Over the past 10 years, this metric has ranged from a low of 91.26 to a high of 166.81. The Drug Manufacturers industry median Days Payable is 90.38. Laurus Labs' value of 163.20 is 80.6% above this industry median. Based on the distribution chart, Laurus Labs ranks #247 out of 927 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Laurus Labs has a GF Score™ of 66/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Laurus Labs' Days Payable compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Laurus Labs ranks #247 out of 927 companies for Days Payable. This puts Laurus Labs in the upper half of its industry. The industry median Days Payable is 90.38. Laurus Labs' value of 163.20 is 80.6% above this benchmark. Historically, Laurus Labs' own Days Payable has ranged from 91.26 to 166.81 over the past decade. While the company's 10-year median is 134.09 vs. the industry median of 90.38, Laurus Labs has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Drug Manufacturers company?
The median Days Payable among Drug Manufacturers companies is 90.38, based on 927 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Laurus Labs's current Days Payable of 163.20 is 80.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Laurus Labs and its competitors. For the Drug Manufacturers industry, the median Days Payable is 90.38 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Laurus Labs's current Days Payable is 163.20, which is 22% above median its own 10-year median of 134.09. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Laurus Labs stock overvalued right now?
Based on GuruFocus' analysis, Laurus Labs (BOM:540222) is currently considered Significantly Overvalued. The stock's GF Value™ is ₹704.96, compared to a current price of ₹1,554.90 — trading 120.6% above its estimated fair value. The current Days Payable is 163.20, which is 22% above median its 10-year median of 134.09 and 80.6% above the Drug Manufacturers industry median of 90.38. Laurus Labs' overall GF Score™ is 66/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Laurus Labs (BOM:540222), the current Days Payable is 163.20 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Laurus Labs (BOM:540222) Overvalued in 2026?
Based on GuruFocus' analysis, Laurus Labs stock appears to be overvalued.
The current stock price of ₹1,554.90 is trading 120.6% above its estimated GF Value™ of ₹704.96.
GuruFocus considers Laurus Labs to be Significantly Overvalued.
Key valuation signals for BOM:540222:
Days Payable: 163.20 (22% above median its 10-year median of 134.09)
GF Value™: ₹704.96 vs. price of ₹1,554.90 (120.6% above fair value)
Industry Position: 80.6% above the Drug Manufacturers median (#247 of 927)
No single metric tells the full story. See the BOM:540222 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Laurus Labs Ltd is a pharmaceutical company based in India. It provides active pharmaceutical ingredients (API) including intermediates, Generic Finished dosage forms (FDF), and Contract Research services. The entity develops APIs and intermediates for select, high-growth antiretrovirals, Hepatitis C and Oncology. It also manufactures APIs in other therapeutic areas, such as anti-asthma, ophthalmology, anti-diabetics, cardiovascular, and proton pump inhibitors, among others. The company has its business presence in India and Outside India of which it derives a majority of revenue from Outside India. The company generates revenue from the sale of API, Intermediates and Formulations, Contract research services, and others.
66GF Score
Get the complete analysis for BOM:540222
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540222 has been successfully added to your 
